Company History
Novartis Pharmaceuticals Corporation (NPC) is the U.S. subsidiary of Novartis AG, a Swiss multinational founded in 1996 by the merger of CibaGeigy and Sandoz. NPC began operations in 1997, inheriting a legacy of more than a century of pharmaceutical innovation from its predecessor companies. The name Novartis blends the Latin novus (new) and artis (science), reflecting the firms commitment to cuttingedge science.
Key milestones include:
- 1998 Launch of Gleevec (imatinib), the first targeted therapy for chronic myeloid leukemia.
- 2003 Introduction of Diovan (valsartan), a leading angiotensin receptor blocker.
- 2015 Acquisition of Alcons eyecare business, expanding into ophthalmology.
- 2020 Completion of the acquisition of Advanced Accelerator Applications, enhancing radiopharmaceutical capabilities.
Business Segments
Novartis structures its operations around three core divisions, each supported by a robust U.S. presence.
Innovative Medicine
Focuses on patented, highvalue medicines across oncology, immunology, neuroscience, ophthalmology, and cardiovascular disease. This segment drives most of the companys R&D spend and contributes the majority of global revenue.
Generics & Biosimilars (Sandoz)
Sandoz provides affordable, highquality generic medicines and biosimilar products. In the United States, Sandoz holds a leading market share in both the generic smallmolecule and biosimilar spaces.
Consumer Health (divested)
Novartis formerly operated a consumer health division; in 2018 it was spun off as a separate entity (GSKNovartis Consumer Health joint venture). The focus of NPC today is solely on prescription medicines and biosimilars.
Research & Development
Novartis invests heavily in R&D, with a 2023 global spend of US$13.0billion, of which about 40% is allocated to the United States. The companys R&D model emphasizes four pillars:
- Targeted therapies: Leveraging genetics and molecular biology to develop drugs that act on specific disease pathways.
- Cell and gene therapies: Pioneering treatments such as CART cell therapy for hematologic cancers.
- Digital health: Partnerships with technology firms to create datadriven clinical trial platforms and patientsupport apps.
- Open innovation: Collaborations with academic institutions, biotech startups, and publicsector initiatives (e.g., the Novartis Institutes for BioMedical Research NIBR).
Figure 1 Approximate allocation of R&D dollars across therapeutic areas (2023).
Product Pipeline
Novartiss pipeline includes more than 70 latestage candidates. Highlights for the U.S. market:
| Therapeutic Area | Candidate (Phase) | Mechanism / Target | Indication |
|---|---|---|---|
| Oncology | Entinostat (Phase III) | HDAC inhibitor | HRpositive breast cancer combined with hormonal therapy |
| Immunology | Ombrelix (Phase II) | IL23 p19 antagonist | Plaque psoriasis |
| Neuroscience | AZD3241 (Phase II) | MAOB inhibitor | Parkinsons disease |
| Ophthalmology | Bimatoprost SR (Phase III) | Sustainedrelease prostaglandin analog | Openangle glaucoma |
| Cardiovascular | EntrestoPause (Phase II) | ARNI formulation | Heartfailure with reduced ejection fraction |
Beyond the pipeline, Novartis has several FDAapproved products that dominate their therapeutic categories, including:
- Kymriah CD19directed CART cell therapy for Bcell acute lymphoblastic leukemia.
- Cosentyx IL17A inhibitor for moderatetosevere plaque psoriasis and ankylosing spondylitis.
- Entresto Sacubitril/valsartan for heart failure.
- Gilenya Fingolimod for relapsing forms of multiple sclerosis.
Corporate Social Responsibility
Novartis integrates access, sustainability, and ethics into its global strategy.
Access to Medicines
The Novartis Access program pledges to provide a bundle of 20 essential medicines at an affordable price of US$1 per treatment course in low and middleincome countries. In the United States, the company runs patientassistance programs that waive copayments for qualifying individuals.
Environmental Sustainability
Novartis aims to be carbonneutral by 2030. U.S. facilities have reduced greenhousegas emissions by 30% since 2018 and have committed to 100% renewable electricity by 2025.
Ethical Conduct
Robust compliance frameworks govern clinical trials, marketing practices, and data privacy. The company publishes an annual Corporate Responsibility Report that details progress against its ESG goals.
Financial Snapshot (2023)
Novartis reported total net sales of US$51.6billion worldwide. In the U.S., the subsidiary contributed approximately US$16.4billion, representing 32% of total revenue.
| Metric | 2023 | 2022 | YoY Change |
|---|---|---|---|
| Total Net Sales (U.S.) | US$16.4bn | US$15.8bn | +3.8% |
| Operating Income (U.S.) | US$4.2bn | US$3.9bn | +7.7% |
| R&D Expenditure (U.S.) | US$5.2bn | US$5.0bn | +4.0% |
| Earnings per Share (EPS) | US$6.00 | US$5.45 | +10.1% |
Growth is driven primarily by oncology launches (e.g., Kisqali for breast cancer) and expanding biosimilar portfolios under the Sandoz brand.
